Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset
The TC-6499 asset sale may provide up to $35.5 million in remaining development, regulatory and commercial milestone payments plus net sales royalties and sub-license fees SOUTH SAN FRANCISCO, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences …